Working… Menu

Cognitive Effects of Immunomodulatory Drugs in MS

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00229502
Recruitment Status : Completed
First Posted : September 29, 2005
Last Update Posted : March 23, 2012
EMD Serono
Information provided by (Responsible Party):
Sharon Lynch, MD, University of Kansas Medical Center

Brief Summary:
The purpose of this study is to examine and compare changes in the specific thinking skills of patients with RRMS who are receiving treatment with one of three immunomodulatory medications (Avonex, Copaxone, or Rebif).

Condition or disease
Multiple Sclerosis

Detailed Description:
In addition this study will compare the patients' personal view of how they are doing, any changes in physical disability, and the frequency and severity of relapses over the three year period.

Layout table for study information
Study Type : Observational
Actual Enrollment : 96 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Comparison of the Cognitive Effects of Three Immunomodulatory Drugs in Relapsing-Remitting Multiple Sclerosis: A Longitudinal Study
Study Start Date : September 2005
Actual Primary Completion Date : September 2011
Actual Study Completion Date : December 2011

Resource links provided by the National Library of Medicine

Subjects receiving Avonex
Subjects receiving Rebif
Subjects receiving Copaxone
Healthy controls

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Multiple sclerosis clinic

Inclusion Criteria:

  • Diagnosis of RRMS for at least one year,
  • Currently on one of three immunomodulatory drugs (Avonex, Copaxone, or Rebif),
  • Visual Acuity is 20/50 or better,
  • patient has four color vision,
  • Must have at least a high school education

Exclusion Criteria:

  • History of head injury, drug/alcohol abuse, and/or psychiatric problems, -current diagnosis of a severe or lifethreatening disease other than MS,
  • currently taking immunosuppressant medication,
  • resides greater than 200 miles from the study site

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00229502

Layout table for location information
United States, Kansas
University of Kansas Medical Center
Kansas City, Kansas, United States, 66160
Sponsors and Collaborators
Sharon Lynch, MD
EMD Serono
Layout table for investigator information
Principal Investigator: Sharon G Lynch, MD University of Kansas Medical Center
Principal Investigator: Douglas R Denney, PhD University of Kansas Medical Center

Layout table for additonal information
Responsible Party: Sharon Lynch, MD, Professor and Director of MS Center, University of Kansas Medical Center Identifier: NCT00229502     History of Changes
Other Study ID Numbers: 10066
First Posted: September 29, 2005    Key Record Dates
Last Update Posted: March 23, 2012
Last Verified: March 2012
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases